107 related articles for article (PubMed ID: 1558322)
1. Bacteriology of 100 consecutive diabetic foot infections and in vitro susceptibility to ampicillin/sulbactam versus cefoxitin.
Borrero E; Rossini M
Angiology; 1992 Apr; 43(4):357-61. PubMed ID: 1558322
[TBL] [Abstract][Full Text] [Related]
2. A multicenter international study on the activity of sulbactam/ampicillin, ampicillin, and cefoxitin against anaerobic bacteria and introduction of a new model of susceptibility testing in mixed infections.
Heizmann WR; Heilmann F; Werner H
Suppl Int J Gynecol Obstet; 1989; 2():7-12; discussion 47-8. PubMed ID: 2679683
[TBL] [Abstract][Full Text] [Related]
3. In-vitro activity of ampicillin/sulbactam against cefoxitin-resistant anaerobic bacteria.
Jones RN; Barry AL
J Antimicrob Chemother; 1988 Jan; 21(1):135-8. PubMed ID: 3356620
[No Abstract] [Full Text] [Related]
4. In vitro activity of ampicillin plus sulbactam against anaerobes compared to ampicillin and cefoxitin.
Heizmann W; Heilmann F; Werner H
Infection; 1987; 15(5):370-4. PubMed ID: 3692611
[TBL] [Abstract][Full Text] [Related]
5. A multicentre study to evaluate the effect of sulbactam/ampicillin combination on anaerobic micro-organisms.
Leone F; Morandotti MG; Mazzella P; Sanna A; Ravizzola G; Colombrita D; Pinzi G; Turano R; Menozzi MG; Lecchini R
J Int Med Res; 1990; 18(3):191-200. PubMed ID: 2193834
[TBL] [Abstract][Full Text] [Related]
6. Association experiments in antimicrobial susceptibility testing of aerobes and anaerobes to ampicillin and ampicillin plus sulbactam.
Heizmann WR; Werner H; Heilmann F
J Chemother; 1989 Jul; 1(4 Suppl):315-6. PubMed ID: 16312418
[No Abstract] [Full Text] [Related]
7. [Comparative in vitro activity of ampicillin, cefoperazone and their combinations with sulbactam, as well as that of other antibiotics against anaerobic organisms].
Rezvan SP; Sidorenko SV; Budanov SV
Antibiot Khimioter; 1995 Apr; 40(4):25-9. PubMed ID: 7654095
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of sulbactam in an in vitro model of mixed aerobic/anaerobic infections.
Heizmann WR; Heilmann F; Egeler B; Werner H
Infection; 1990; 18(2):117-21. PubMed ID: 2332245
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic interchange of ampicillin-sulbactam for cefoxitin.
Lawrenz CA; Cole P; Theodorou A; Cook RL; Bermann L
Am J Hosp Pharm; 1991 Oct; 48(10):2150-4. PubMed ID: 1781470
[TBL] [Abstract][Full Text] [Related]
10. Cefoxitin in the treatment of aerobic and anaerobic infections. Prospective correlation of in vitro susceptibility methods with clinical outcome.
Goldstein EJ; Citron DM; Cole RE; Rangel DM; Seid AS; Ostovari MO
Hosp Pract (Off Ed); 1990 Oct; 25 Suppl 4():38-45. PubMed ID: 2120272
[TBL] [Abstract][Full Text] [Related]
11. [The effect of a combination of ampicillin and sulbactam against clinical anaerobic isolates].
Werner H; Heizmann W; Heilmann F
Arzneimittelforschung; 1988 Jul; 38(7):866-8. PubMed ID: 3207432
[TBL] [Abstract][Full Text] [Related]
12. Comparative activity of cefoxitin, ampicillin/sulbactam, and imipenem against clinical isolates of Escherichia coli and Klebsiella pneumoniae.
Shungu DL; Ponticas S; Gill CJ
Clin Ther; 1989; 11(3):315-8. PubMed ID: 2663161
[TBL] [Abstract][Full Text] [Related]
13. Bactericidal activity of low-dose ceftizoxime plus metronidazole compared with cefoxitin and ampicillin-sulbactam.
Freeman CD; Nightingale CH; Nicolau DP; Belliveau PP; Tessier PR; Fu Q; Xuan DW; Quintiliani R
Pharmacotherapy; 1994; 14(2):185-90. PubMed ID: 8197037
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
Antimicrob Agents Chemother; 2008 Feb; 52(2):761-6. PubMed ID: 18070958
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of meropenem compared with imipenem, metronidazole, ampicillin, and ampicillin/sulbactam against anaerobes.
Schumacher U; Manncke B; Gerbracht K; Werner H
Arzneimittelforschung; 1994 Jul; 44(7):859-62. PubMed ID: 7945523
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of sulbactam-ampicillin for the treatment of severe diabetic foot infections.
Akova M; Ozcebe O; Güllü I; Unal S; Gür D; Akalin S; Tokgözoglu M; Telatar F; Akalin HE
J Chemother; 1996 Aug; 8(4):284-9. PubMed ID: 8873834
[TBL] [Abstract][Full Text] [Related]
17. Broth-disk elution tests to predict the susceptibility of anaerobic bacteria to the ampicillin-sulbactam combination.
Jones RN
Diagn Microbiol Infect Dis; 1990; 13(4):353-5. PubMed ID: 2076598
[TBL] [Abstract][Full Text] [Related]
18. [Experience with microbiological studies of the diabetic foot].
Kajetán M; Konkoly TM; Jermendy G
Orv Hetil; 1995 Oct; 136(40):2161-4. PubMed ID: 7566949
[TBL] [Abstract][Full Text] [Related]
19. Ampicillin/sulbactam and cefoxitin in the treatment of cutaneous and other soft-tissue abscesses in patients with or without histories of injection drug abuse.
Talan DA; Summanen PH; Finegold SM
Clin Infect Dis; 2000 Aug; 31(2):464-71. PubMed ID: 10987706
[TBL] [Abstract][Full Text] [Related]
20. Serum bactericidal activity against aerobes and anaerobes of volunteers receiving cefoxitin or cefotetan.
Cruciani M; Navarra A; Bono L; Concia E
Chemioterapia; 1988 Aug; 7(4):261-3. PubMed ID: 3180306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
